Adaptive Biotechnologies Corp (ADPT) experienced a significant surge of 8.20% during intraday trading on Friday, driven by positive analyst actions.
JPMorgan analyst Sebastian Sandler raised the firm's price target on Adaptive Biotechnologies to $21 from $20 and maintained an Overweight rating. Simultaneously, BTIG increased its price target to $22 from $21 and kept a Buy rating on the shares following the company's Q4 results.
These analyst upgrades have bolstered investor sentiment towards the biotechnology firm, contributing to the notable price appreciation during the trading session.